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Altered terminal glycosylation, with increased fucosylation and decreased sialylation, is a hallmark of the cystic fibrosis (CF)
glycosylation phenotype. The glycosylation phenotype of CF airway epithelial cells has been modulated by the expression of wtCFTR.
Understanding the effects of mutant CFTR on glycosylation may provide further insight into the regulation of glycoconjugate processing as
well as new approaches to the therapy of CF.
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The precise role of mutant CFTR in the pathogenesis of isx) were found in CF compared to non-CF airway cells [3].CF remains to be elucidated. Our group has focused on the
alterations in terminal glycosylation of the airway cell sur-
face, which is the site of the initiation and progression of CF
lung disease [1].
Glycosylation requires the coordinated action of specific
glycosyltransferases (GTs), in the smooth ER and the Golgi
apparatus. Specific carbohydrates structures on the cell
surface mediate the binding and adhesion of a variety of
molecules and microorganisms [2].
Dische and colleagues demonstrated increased ratio of
fucose to sialic acid in intestinal mucins obtained from CF
patients and since then over forty different studies have
detailed a specific glycosylation phenotype present in CF
tissues. This CF glyco phenotype of increased fucose and
decreased sialic acid in the terminal positions of membrane
glycoconjugates has been confirmed by different methods in
multiple cells types [1].
Our studies have focused on the airway epithelium as the
site of the most lethal pathology in CF. Similar to results
obtained from earlier fibroblast studies, increased fucosyl
residues (Fuc) linked a1,3 or 4 to N-acetylglucosamine
(Fuca1,3/4GlcNAc, i.e., structures termed Lewisa and Lew-1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2004.05.021
Abbreviations: Fuc, fucose; NeuAc, acetylneuraminic acid (or sialic
acid).
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E-mail address: scanlin@email.chop.edu (T.F. Scanlin).Also, significantly less terminal sialic acid residues were
found on CF membrane glycoproteins compared to non-CF.
In airway epithelial cells, the glycosylation phenotype of
increased Fuca1,3/4GlcNAc and decreased sialic acid is
modulated by the degree of wt CFTR expression [3]. When
wt copies of the CFTR gene are transferred into CF airway
epithelial cells so that these cells express normal CFTR
protein, the amount of sialic acid and Fuca1,3/4GlcNAc
found on membrane glycoproteins change to levels seen in
non-CF cells. Conversely, when wtCFTR is no longer
expressed in the CF airway epithelial cells, the amount of
sialic acid decreases and Fuca1,3/4GlcNAc increases. The
dependence on CFTRwas seen in primary and corresponding
immortalized cells. Therefore, in airway epithelial cells, the
presence of CFTR affects glycosylation.
It has also been shown that not all fucose moieties are
increased in CF airway cells. Specifically, the amount of
fucose in a1,2 linkage to galactose is decreased in CF
airway cells compared to non-CF airways. The ratio of
Fuca1,3/4GlcNAc: Fuca1,2Gal reflects the ratio of
Fuca1,3/4GlcNAc: sialic acid in airway cells. Moreover,
the amount of Fuca1,2Gal is increased when wt-CFTR
cDNA is transferred into and expressed in CF airway
epithelial cells [4].
Since the detailing of the glycosylation phenotype, our
laboratory has been interested in the elucidation of the
mechanism for CFTR-dependent altered glycosylation ined by Elsevier B.V. All rights reserved.
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scriptional expression and activity of sialyl- and a1,3 fuco-
syltransferases, as well as relevant enzymes in the sialylation
and fucosylation pathways in CF and non-CF cells have
yielded no significant differences in the enzymes required for
glycosylation [4,6,7]. This data supports the proposal that the
compartmentalization of the glycosyltransferases in the Gol-
gi apparatus is affected by CFTR [5,8]. Preliminary experi-
ments localizing sialyl- and fucosyltransferases by confocal
microscopy have provided evidence to support this hypoth-
esis [7]. Further experiments are underway to confirm these
findings by immunoelectron microscopy and subcellular
fractionation.
Pseudomonas aeruginosa is the major pathogen in
chronic CF lung disease. A recent crystallography study
provided the structural basis for increased adhesion by P.
aeruginosa in CF airways [9]. The focus of their study was
PA-IIL, a P. aeruginosa lectin that binds to specific carbo-
hydrates and is involved in colonization. It was shown that
PA-IIL contains an anionic ‘‘dock’’ which allows optimal
binding of fucosylated carbohydrate structures. Therefore,
the mechanism of increased and efficient P. aeruginosa
adherence may be due to the increased constitutive expres-
sion of terminal a1,3/4 fucose-containing carbohydrate
motifs on CF airway epithelial cell membranes.
The CF glycophenotype of increased Fuca1,3GlcNAc,
expressed as the Lewisx epitope may be a reason for the
high incidence of P. aeruginosa pulmonary infection in CF.
Our laboratory is exploring the possibility of the adminis-
tration of synthetic carbohydrates, to decrease bacterial
binding on the surfaces of CF airway cells, ‘‘Glycomimetic
blockade’’ therapy could prove to be an effective, targeted
therapy to prevent the infection of CF airways. In addition,
our laboratory is developing methods to pharmacologically
decrease fucosylation of CF airways. It is our hope that suchstrategies can translate into effective therapies to improve
the quality of life and survival of patients with CF.Acknowledgements
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